Payment overview · 2025
General Payments
$1,211.01
27 reported records · 14 companies
Healthcare provider profile · identity verified
Jeremy Michael Huff, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BEAUMONT, TX · NPI 1982802419
Verified facts
What the public records show
CMS Open Payments records show Jeremy Michael Huff, D.O. received $1,211.01 in general payments during 2025 across 27 reported records.
Abbott Laboratories accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 804 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $600.14 | 49.6% | 4 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $127.09 | 10.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $99.66 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.36 | 5.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.96 | 5.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.96 | 3.8% | 3 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $43.06 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.51 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.96 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.40 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.76 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.50 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.49 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.16 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $676.53 | 24 |
| Travel and Lodging | $534.48 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $600.14 | 4 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $127.09 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $99.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.96 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.53 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.53 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.53 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.96 | 3 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 211 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
186 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
211 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
804 | 103 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1738 | 347 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1447 | 324 |
| Gabapentin | Gabapentin | 1294 | 286 |
| Montelukast Sodium | Montelukast Sodium | 952 | 225 |
| Amlodipine Besylate | Amlodipine Besylate | 928 | 215 |
| Furosemide | Furosemide | 915 | 194 |
| Pantoprazole Sodium | Pantoprazole Sodium | 844 | 198 |
| Eliquis | Apixaban | 804 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 799 | 216 |
| Metoprolol Succinate | Metoprolol Succinate | 719 | 188 |
| Allopurinol | Allopurinol | 700 | 166 |
| Losartan Potassium | Losartan Potassium | 675 | 173 |
| Lisinopril | Lisinopril | 652 | 161 |
| Potassium Chloride | Potassium Chloride | 620 | 118 |
| Omeprazole | Omeprazole | 547 | 157 |
| Escitalopram Oxalate | Escitalopram Oxalate | 532 | 132 |
| Simvastatin | Simvastatin | 516 | 112 |
| Donepezil Hcl | Donepezil Hcl | 473 | 88 |
| Tramadol Hcl | Tramadol Hcl | 465 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 455 | 114 |
| Clopidogrel | Clopidogrel Bisulfate | 453 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 430 | 117 |
| Trazodone Hcl | Trazodone Hcl | 410 | 87 |
| Duloxetine Hcl | Duloxetine Hcl | 408 | 87 |
| Famotidine | Famotidine | 388 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 384 | 80 |
| Sertraline Hcl | Sertraline Hcl | 369 | 85 |
| Carvedilol | Carvedilol | 368 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 361 | 70 |
| Metformin Hcl | Metformin Hcl | 359 | 82 |
| Alprazolam | Alprazolam | 350 | 88 |
| Meloxicam | Meloxicam | 333 | 92 |
| Memantine Hcl | Memantine Hcl | 320 | 61 |
| Buspirone Hcl | Buspirone Hcl | 315 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 299 | 70 |
| Bupropion Xl | Bupropion Hcl | 275 | 65 |
| Ezetimibe | Ezetimibe | 275 | 68 |
| Lorazepam | Lorazepam | 256 | 66 |
| Azithromycin | Azithromycin | 252 | 207 |
| Fluticasone Propionate | Fluticasone Propionate | 249 | 99 |
| Methylprednisolone | Methylprednisolone | 248 | 205 |
| Metformin Hcl Er | Metformin Hcl | 237 | 62 |
| Fenofibrate | Fenofibrate | 228 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 211 | 43 |
| Myrbetriq | Mirabegron | 211 | 31 |
| Ozempic | Semaglutide | 211 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 203 | 49 |
| Xarelto | Rivaroxaban | 200 | 26 |
| Divalproex Sodium | Divalproex Sodium | 197 | 28 |
| Spironolactone | Spironolactone | 197 | 44 |
| Synthroid | Levothyroxine Sodium | 186 | 47 |
| Mounjaro | Tirzepatide | 177 | 36 |
| Warfarin Sodium | Warfarin Sodium | 173 | 16 |
| Finasteride | Finasteride | 171 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 49 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 154 | 112 |
| Jardiance | Empagliflozin | 149 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 144 | 36 |
| Pregabalin | Pregabalin | 144 | 30 |
| Clonazepam | Clonazepam | 136 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 135 | 26 |
| Albuterol Sulfate | Albuterol Sulfate | 132 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 132 | 21 |
| Temazepam | Temazepam | 132 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 131 | 98 |
| Levetiracetam | Levetiracetam | 131 | 21 |
| Mirtazapine | Mirtazapine | 128 | 31 |
| Atenolol | Atenolol | 126 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 30 |
| Glimepiride | Glimepiride | 112 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 112 | 78 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 31 |
| Januvia | Sitagliptin Phosphate | 103 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 102 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 23 |
| Novolin R | Insulin Regular, Human | 97 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 22 |
| Ramipril | Ramipril | 94 | 22 |
| Celecoxib | Celecoxib | 93 | 27 |
| Nifedipine Er | Nifedipine | 93 | 27 |
| Farxiga | Dapagliflozin Propanediol | 88 | 12 |
| Levofloxacin | Levofloxacin | 86 | 64 |
| Estradiol | Estradiol | 80 | 27 |
| Glipizide | Glipizide | 79 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 19 |
| Baclofen | Baclofen | 75 | 12 |
| Entresto | Sacubitril/Valsartan | 73 | suppressed |
| Latanoprost | Latanoprost | 69 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 19 |
| Prednisone | Prednisone | 69 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Aripiprazole | Aripiprazole | 65 | suppressed |
| Glipizide Er | Glipizide | 65 | 17 |
| Lovastatin | Lovastatin | 63 | 14 |
| Risedronate Sodium | Risedronate Sodium | 63 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 20 |
| Valsartan | Valsartan | 62 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 18 |
| Clonidine Hcl | Clonidine Hcl | 58 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 54 |
| Colesevelam Hcl | Colesevelam Hcl | 56 | 12 |
| Torsemide | Torsemide | 56 | suppressed |
| Fluconazole | Fluconazole | 55 | 38 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 17 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 18 |
| Topiramate | Topiramate | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 13 |
| Ranolazine Er | Ranolazine | 51 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 50 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 50 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 38 |
| Risperidone | Risperidone | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 42 |
| Linzess | Linaclotide | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 46 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 13 |
| Megestrol Acetate | Megestrol Acetate | 46 | 14 |
| Irbesartan | Irbesartan | 45 | 14 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Eszopiclone | Eszopiclone | 44 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Lactulose | Lactulose | 42 | 16 |
| Acyclovir | Acyclovir | 41 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Nystatin | Nystatin | 41 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 39 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 31 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 24 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 38 | suppressed |
| Diazepam | Diazepam | 37 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 12 |
| Novolog | Insulin Aspart | 37 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 35 |
| Promethazine Hcl | Promethazine Hcl | 35 | 22 |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 27 |
| Azelastine Hcl | Azelastine Hcl | 33 | 12 |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 21 |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 32 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 25 |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 30 | 25 |
| Gemtesa | Vibegron | 30 | suppressed |
| Clonidine | Clonidine | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | 22 |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 25 | 22 |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | 12 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Mirabegron Er | Mirabegron | 24 | 12 |
| Pilocarpine Hcl | Pilocarpine Hcl | 24 | suppressed |
| Tresiba | Insulin Degludec | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 14 |
| Anastrozole | Anastrozole | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 14 |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Verquvo | Vericiguat | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Buprenorphine | Buprenorphine | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 16 |
| Colchicine | Colchicine | 16 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Ursodiol | Ursodiol | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,211.01 · 27 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, ATRICLIP LAA EXCLUSION SYSTEM, COMIRNATY, DAXXIFY, GVOKE HYPOPEN, INCEPTIV, LEQVIO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNERGY ABLATION SYSTEM, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error